Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2022-03-01 Regulatory Filings
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a short filing (3885 characters) reporting a press release about patent applications, attached as Exhibit 99.1. It explicitly states it is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and does not contain financial statements or detailed financial data. The document is not an annual or quarterly report, nor an earnings release, but a regulatory announcement of a material event. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-03-01 English
Delisting Announcement 2022
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 18, 2022, by Enveric Biosciences, Inc. The key content is under Item 3.01, which is a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The document details that the company received a letter from Nasdaq indicating it did not meet the minimum bid price requirement for continued listing and describes the compliance period and potential consequences. There is no financial data or report attached; it is an official notice regarding the listing status of the company's stock. This matches the definition of a Delisting Announcement (DLST). The document length is just over 5,000 characters, but the content clearly focuses on delisting notice rather than a financial report or other filing type.
2022-02-18 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common stock and warrants, including details about the offering size, pricing, use of proceeds, and related legal opinions. It also references press releases about the offering. There are no financial statements or detailed financial analysis included, and the document is not an annual or quarterly report. The primary focus is on a capital raising event and related agreements. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (8066 characters) supports it being a substantive filing rather than a brief announcement or certification.
2022-02-15 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and warrants by Enveric Biosciences Inc. It includes detailed offering terms, underwriting information, risk factors, and legal disclaimers. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly an update on financing activities and capital structure changes related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief note, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear nature of the document as a prospectus supplement for a securities offering.
2022-02-15 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5, which is an amended preliminary prospectus supplement filed pursuant to Rule 424(b)(5). It relates to an offering of common stock and warrants by Enveric Biosciences Inc. The text includes detailed information about the securities being offered, underwriting, risk factors, and legal disclaimers. This type of document is a capital markets filing related to fundraising and securities issuance, specifically a prospectus supplement for a public offering. It is not a financial report, earnings release, management discussion, or any other type of report. Therefore, it fits the category of Capital/Financing Update (CAP).
2022-02-11 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to an offering of common stock and warrants by Enveric Biosciences Inc. It includes detailed information about the securities being offered, underwriting, risk factors, use of proceeds, and other offering terms. This type of document is a capital raising disclosure used to inform investors about a new financing transaction. It is not a financial report, earnings release, management discussion, or regulatory filing unrelated to capital raising. The presence of terms like 'prospectus supplement', 'offering', 'underwriting', and detailed securities description clearly identifies this as a Capital/Financing Update. The document length and content confirm it is the actual offering document, not just an announcement or a brief summary. Therefore, the correct classification is Capital/Financing Update (CAP).
2022-02-10 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.